IL-15 in CAR engineering: striking an efficacy–safety balance
Yan-Ruide Li, Yichen Zhu, Lili Yang
Abstract
Interleukin (IL)-15 engineering in chimeric antigen receptor (CAR)-cell therapy has demonstrated promising antitumor efficacy against both hematological malignancies and solid tumors in recent clinical trials. However, increased cytokine release syndrome (CRS) toxicity is primarily observed in conventional CAR-T cells, underscoring the need to balance safety and efficacy in IL-15-enhanced CAR therapy for clinical application.
Topics & Concepts
Chimeric antigen receptorCytokine release syndromeMedicineClinical trialCytokineToxicityImmunologyImmunotherapyBalance (ability)Clinical efficacyCancer researchInternal medicineImmune systemPhysical therapyCAR-T cell therapy researchImmune Cell Function and InteractionElectrostatic Discharge in Electronics